intellectual property litigation

Patent and other intellectual-property lawsuits, by or against the company.

Exposure · 6 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • CAPR CAPRICOR THERAPEUTICS, INC.

    Exposed“Capricor is defending securities class actions and shareholder derivative matters, and Mesoblast sued in July 2026 alleging patent infringement related to Deramiocel.”

    Latest 10-QQ3 FY2026NegativeRestructuring ·

    Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.

    • Revenue$0vs $0 year ago
    • Net income−$42.7MYoY −73.6%
  • CDNA CareDx, Inc

    Exposed“Patent challenges, infringement claims, or loss of licensed technology could require costly litigation, royalties, redesign or cessation of sales.”

    Latest 10-QQ3 FY2026Positive ·

    Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.

    • Revenue$139.4MYoY +39.3%
    • Net income$19.3Mvs $1.7M year ago
  • Latest 10-QQ3 FY2026Legal / investigation ·

    Section 45X credits lift profits despite weaker module shipments, but delayed collections and rising inventory strain cash flow.

    • Revenue$1.2BYoY −22.8%
    • Net income$571.1MYoY +25.2%
  • INTC Intel

    Exposed“VLSI is Intel’s principal quantified litigation exposure, with several proceedings and outcomes unresolved.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Hyperscaler demand for premium server chips offsets client weakness; Kiryat Gat fab accident adds Q4 costs.

    • Revenue$16.5BYoY +20.9%
    • Net income$3.3BYoY −18.3%
  • NYT New York Times Company

    Exposed“Unauthorized AI scraping, copying and use of NYT content or trademarks may divert traffic and reduce subscriber, advertiser, referral and licensing demand, as well as damage brand trust through inaccurate attribution.”

    Latest 10-QQ3 FY2026PositiveLegal / investigation ·

    Digital subscriber gains and post-promotion pricing offset print declines, lifting margins despite higher newsroom spending

    • Revenue$768.5MYoY +9.7%
    • Net income$97.4MYoY +19.2%
  • SCTX Scribe Therapeutics, Inc.

    Exposed“Challenges, infringement claims, license termination, unavailable rights or unfavorable licensing terms could require payments or redesign, block programs or weaken exclusivity.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

Feedback